Biliopancreatic disorder
Conditions
Interventions
1. Propofol group: a slow initial intravenous bolus of 0.8 mg/kg and maintain a continuous infusion of 3 mg/kg/h
2. Midazolam group: an initial bolus of 0.06mg/kg and inremental doses of 0.03mg/kg at
Sponsors
Hiroshima University hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patient over age 20 2. Patient who is clinically indicated for ERCP for examination or treatment of biliopancreatic disorder 3. Patient who has agreed to conditions after receiving an explanation about the contents of the present clinical study and who has signed the consent form
Exclusion criteria
Exclusion criteria: 1. Patients who are deemed inappropriate to sedation because of bad general ccondition 2. Patients with severe cardiovascular or respiratory disorder 3. Patients who have decompensated liver cirrhosis 4. Patients who have experienced a serious adverse effect by propofol or midazolam 5. Patient with known contraindications for propofol or midazolam 6. Pregnant or potentially pregnant women 7. Other patients who are in the opinion of the caring investigator unfit for enrollment in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| sedation efficacy rate | — |
Countries
Japan
Contacts
Public ContactTomoyuki Minami
Hiroshima University hospital Department of gastroenterology and metabolism
Outcome results
None listed